Tests an exercise program during chemotherapy in young people with sarcoma
Tests an exercise program to see how it affects chemotherapy in young people with sarcoma.
Plain-language title generated from the registry record
Registry title: Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients
Key facts
- Where
- Miami, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 39 years old?
Source: NCT07359911, who can take part
Where in United States
- University of MiamiMiami, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Miami
- Trial code
- NCT07359911
- Record updated
- 18 February 2026
- Original description
The purpose of this study is to determine the effects of a multimodal exercise intervention on chemotherapy uptake in newly diagnosed pediatric, adolescent and young adult (AYA) Sarcoma patients.Read full original descriptionShow less
Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients (ACTIVE-SARC)
The purpose of this study is to determine the effects of a multimodal exercise intervention on chemotherapy uptake in newly diagnosed pediatric, adolescent and young adult (AYA) Sarcoma patients.
Inclusion: Diagnosis of Sarcoma; Pediatric or AYA (12-39 years old); Able to provide written informed consent; Able to speak, read, and understand English or Spanish; Initiating first-line systemic therapy (Doxorubicin, Ifosfamide, Gemcitabine, Docetaxel, Trabectedin, Vincristine, Irinotecan, Temozolomide, Topotecan, Etoposide, Dacarbazine, Pazopanib, Tazemetostat, Imatinib, Sunitinib, Pembrolizumab, Nivolumab, Ipilumumab, Regorafenib, Atezulimumab). Participants can be enrolled up to 90 days after starting firstline systemic therapy; Approval from a medical oncology provider to participate; Having not consistently (not equal to or more than 50% of the time) engaged in more than 90 minutes of moderate or 45 minutes of vigorous physical activity per week over the past 3 months; Having not consistently engaged in resistance training 2 or more days per week over the past 3 months.
Exclusion: More than 90 days from initiation of first-line systemic therapy; Presence of a severe medical condition or psychiatric condition or medications that would preclude participation of the study intervention, as determined by the patient's provider and study clinician; < 12 or >39 years old; Unable to provide consent; Unable to read or understand English or Spanish; Oxygen-dependent; Unable to walk 2 blocks without assistance (excluding canes); Unstable bone metastases.